These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20725732)

  • 21. [New trends in rheumatology. The Danish Society of Rheumatology].
    Andersen LS; Gam AN; Hansen A; Kollerup G; Rasmussen C; Rasmussen JM; Schiøttz-Christensen B; Slot O; Thamsborg G
    Ugeskr Laeger; 2003 Mar; 165(12):1255. PubMed ID: 12701305
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 28. [Rheumatology].
    Scherer HU; Burmester GR
    Internist (Berl); 2005 Aug; 46(8):882-91. PubMed ID: 15997385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.
    Raghunath S; Hijjawi R; Hoon E; Shanahan EM; Goldblatt F
    Clin Rheumatol; 2019 Oct; 38(10):2699-2707. PubMed ID: 31172365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biologics and further new drugs for rheumatic diseases since 2000].
    Krüger K
    Orthopade; 2018 Nov; 47(11):906-911. PubMed ID: 30280235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.
    Geri G; Dadoun S; Bui T; Del Castillo Pinol N; Paternotte S; Dougados M; Gossec L
    BMC Infect Dis; 2011 Nov; 11():304. PubMed ID: 22046967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity reactions to biologics used in rheumatology.
    Matucci A; Nencini F; Maggi E; Vultaggio A
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1263-1271. PubMed ID: 31639316
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 34. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.
    Zavada J; Dixon WG; Askling J;
    Ann Rheum Dis; 2014 Mar; 73(3):628. PubMed ID: 24058015
    [No Abstract]   [Full Text] [Related]  

  • 35. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologics in children's autoimmune disorders: efficacy and safety.
    Breda L; Del Torto M; De Sanctis S; Chiarelli F
    Eur J Pediatr; 2011 Feb; 170(2):157-67. PubMed ID: 20556424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.
    Nurmohamed M; Choy E; Lula S; Kola B; DeMasi R; Accossato P
    Drug Saf; 2018 May; 41(5):473-488. PubMed ID: 29318514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rheumatology training and research in Iran.
    Khabbazi A; Soroosh M
    Rheumatol Int; 2019 Aug; 39(8):1307-1319. PubMed ID: 31111293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in Pediatric Rheumatology: July 2015-June 2016.
    Sharma A; Vignesh P; Jindal AK; Gupta A
    Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.